Cadila Healthcare - German Remedies launches 'Novolizer' a patented device for Asthma & COPD

Cadila Healthcare Ltd has announced that German Remedies, a part of the Zydus Cadila Group has launched Novolizer a device for Asthma and COPD. The technology for the device is provided by Meda Pharma of Sweden alongwith exclusive rights to manufacture and market Novolizer in India, Novolizer is a third-generation refillable, breath activated multiple dose dry powder inhaler device and can be used by patients suffering from Asthma and COPD.

Asthma is a chronic, debilitating respiratory condition with sudden, unpredictable and potentially life-threatening effects. It is estimated that there are more than 20 million asthmatics in India. The treatment of Asthma requires constant vigilance and the active involvement of patients to monitor, anticipate and promptly respond to the onset of asthmatic attacks. Chronic Obstructive Pulmonary Disease (COPD) is a lung disease that is progressive and not fully reversible. COPD obstructs the airways and makes breathing difficult. Patients with COPD suffer from frequent cough, mucus production and shortness of breath which makes even walking a short distance, a difficult task.

In treating Asthma and COPD, patient compliance and availing the right dose at the right time can be crucial. Several clinical studies have revealed limitations in the development of inhalation devices, which prevent almost half of all asthma patients from inhaling correctly. This leads to poor asthma control despite effective substances being available to treat Asthma.

An ideal inhaler effectively delivers the drug that a patient requires through the airways which are usually narrowed in an asthmatic condition. It also helps in the exact dose being deposited in the lungs irrespective of the inhalation technique.

Novolizer fulfills all the elements of an ideal inhaler and is currently the only third-generation inhaler available across the world. With superior features, Novolizer can be used by people of different age groups, even children. It has a patient-friendly, multiple feedback mechanism, which can guide the user through the correct inhalation process. In addition, Novolizer also has an intelligent dose counter, which resets only after correct inhalation. This would also help in monitoring patient compliance. Among all the devices in the market, Novolizer has one of the best lung depositions, The currently available Multiple Dose Dry Powder Inhalers have limitations of being non-refillable and also have higher costs per dose.

German Remedies currently markets Formonide, Forair, Combimist, etc. in the respiratory segment and is ranked 2nd in the participated market.

Source : Equity Bulls

Keywords